Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen

The goal of this observational study aims to observe and evaluate the efficacy and safety of a liposomal doxorubicin containing regimen in the postoperative adjuvant treatment of breast cancer patients.

Inclusion Criteria:Female, aged 18-75 years;Primary breast cancer diagnosed histopathologically;Adjuvant chemotherapy regimens include liposomal doxorubicin;ECoG PS score: 0-1 points;Left ventricular ejection fraction (LVEF) ≥ 55%;Estimated survival ≥ 6 months;Major organ function is normal, i.e. meets the following criteria:① And white blood cells ≥ 4.0 × 10 9 / L, neutrophil count (ANC) ≥ 1.5 × 10 9 /L；② Platelets ≥ 100 × 10 9 /L；③ And hemoglobin ≥ 10 g / dl; ④ Serum creatinine ≤ 1.5 × ⑤ the upper limit of normal (ULN) Mmol / L and aspartate transaminase (AST) ≤ 2.5× ULN；⑥ Alanine transaminase (ALT) ≤ 2.5 × ULN；⑦ Total bilirubin ≤ 1.5 × ULN；⑧ Serum creatinine ≤ 1.5 × ULN；Subjects voluntarily join this study, sign the informed consent form, have good compliance and cooperate with follow-up.Exclusion Criteria:Pregnant, lactating patients;Breast cancer has been found to have distant metastasis;Those with peripheral nervous system disorders caused by the disease or with a history of significant mental disorders and central nervous system disorders;Those with severe infection or active peptic ulcer requiring treatment;Allergic to chemotherapy drugs;Cancer free period less than 5 years except for cured basal cell carcinoma of the skin and cured carcinoma in situ of the cervix;Severe liver disease (e.g., cirrhosis, etc.), renal disease, respiratory disease, or uncontrolled diabetes;Patients who are participating in other clinical trials or within a month.